Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- DIAPEDIA, LLC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- VCA7MUS7HJK3
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (Adapted from the Investigator's Abstract): Gastrointestinal (GI)
ulceration and hemorrhage is a major health problem in our country representing
billions of dollars in health care costs and lost revenues from work place.
Despite sophisticated therapeutic agents, the disturbing problem of high
recurrence rate of bleeding, even after complete healing, remains. About one
third of the patients treated with traditional ulcer therapy have recurrent
hemorrhage. There is a need for developing new drugs that can arrest
hemorrhage. In our pilot work we have shown that the organic extract of Chinese
herbal preparation, Yunnan baiyao, has favorable influence on severe intestinal
syndromes produced by indomethacin, and is also effective in promoting the
healing and preventing GI ulcers in rat models. We have also shown that the
extract contains at least two potent factors that induce aggregation of human
platelets. We propose in this SBIR application to optimize methods for
extraction as well as establish the molecular identity and mode of action of
active principles that exhibit platelet aggregatory activities. We plan to
carry out biological assays specific for anti-ulcerative and anti-hemorrhagic
properties. The Phase I study will lay the foundation essential for the full
development of the active factors into anti-hemorrhagic drug in Phase II
studies.
PROPOSED COMMERCIAL APPLICATION:
The market for an effective and safe therapeutic agent to treat several types of
hemorrhagic disorder notably bleeding from esophageal varices, gastric and
duodenal ulcers will be enormous.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Research funding history
14 SBIR/STTR records share this UEI (2001–2017). Reported award amounts total $9,092,425. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, Department of Defense
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards